MorphoSys AG (ETR:MOR) Given Average Rating of “Buy” by Brokerages
Shares of MorphoSys AG (ETR:MOR) have been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is €69.57 ($81.85).
A number of equities research analysts have recently commented on the stock. Independent Research GmbH set a €77.00 ($90.59) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research note on Monday. Deutsche Bank AG set a €90.00 ($105.88) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research note on Monday. J P Morgan Chase & Co set a €62.00 ($72.94) price objective on shares of MorphoSys AG and gave the stock a “neutral” rating in a research note on Friday, August 4th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price objective on shares of MorphoSys AG and gave the stock a “neutral” rating in a research note on Friday, August 4th. Finally, Berenberg Bank set a €68.00 ($80.00) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research note on Thursday, August 3rd.
MorphoSys AG (ETR MOR) traded down 0.798% during trading on Friday, hitting €56.049. 4,188 shares of the company were exchanged. The firm’s 50 day moving average price is €62.27 and its 200-day moving average price is €57.58. The stock’s market capitalization is €1.63 billion. MorphoSys AG has a 1-year low of €35.72 and a 1-year high of €70.90.
TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/11/morphosys-ag-etrmor-given-average-rating-of-buy-by-brokerages.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Stock Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related stocks with our FREE daily email newsletter.